4.6 Article

B-cell receptor signaling induces proteasomal degradation of PDCD4 via MEK1/2 and mTORC1 in malignant B cells

期刊

CELLULAR SIGNALLING
卷 94, 期 -, 页码 -

出版社

ELSEVIER SCIENCE INC
DOI: 10.1016/j.cellsig.2022.110311

关键词

Chronic lymphocytic leukemia; Lymphoma; PDCD4; mRNA translation; Ibrutinib

资金

  1. Medical Research Council, Cancer Research UK [C2750/A23669, C42023/A29370]
  2. Southampton Experimental Cancer Medicine and Cancer Research Centres [C34999/A18087, C24563/A15581]

向作者/读者索取更多资源

This study provides new insights into the regulation of mRNA translation in B-cell malignancies, highlighting the importance of combining kinase inhibitors to target translation control and MYC expression.
B-cell receptor (BCR) signaling plays a major role in the pathogenesis of B-cell malignancies and is an established target for therapy, including in chronic lymphocytic leukemia cells (CLL), the most common B-cell malignancy. We previously demonstrated that activation of BCR signaling in primary CLL cells downregulated expression of PDCD4, an inhibitor of the translational initiation factor eIF4A and a potential tumor suppressor in lymphoma. Regulation of the PDCD4/eIF4A axis appeared to be important for expression of the MYC oncoprotein as MYC mRNA translation was increased following BCR stimulation and MYC protein induction was repressed by pharmacological inhibition of eIF4A. Here we show that MYC expression is also associated with PDCD4 down regulation in CLL cells in vivo and characterize the signaling pathways that mediate BCR-induced PDCD4 down regulation in CLL and lymphoma cells. PDCD4 downregulation was mediated by proteasomal degradation as it was inhibited by proteasome inhibitors in both primary CLL cells and B-lymphoma cell lines. In lymphoma cells, PDCD4 degradation was predominantly dependent on signaling via the AKT pathway. By contrast, in CLL cells, both ERK and AKT pathways contributed to PDCD4 down-regulation and dual inhibition using ibrutinib with either MEK1/2 or mTORC1 inhibition was required to fully reverse PDCD4 down-regulation. Consistent with this, dual inhibition of BTK with MEK1/2 or mTORC1 resulted in the strongest inhibition of BCR-induced MYC expression. This study provides important new insight into the regulation of mRNA translation in B-cell malignancies and a rationale for combinations of kinase inhibitors to target translation control and MYC expression.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据